NHS Eligibility for Weight Loss Injections: What the Current Criteria Actually Require

Step 1: Check whether NICE's approval covers your situation

NICE recommended tirzepatide (Mounjaro) for NHS use in December 2024 under technology appraisal TA1026. The headline threshold is a BMI of 35 or above, alongside at least one weight-related comorbidity. The five qualifying conditions are: type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea, and cardiovascular disease. If your BMI falls into that range and you have one of those conditions, you are broadly within NICE's recommended population, though that does not automatically translate to an NHS prescription right now.

One important adjustment: NICE applies thresholds that are 2.5 kg/m² lower for people of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds, reflecting known differences in how excess weight affects health at a given BMI. So the effective BMI threshold for those groups is 32.5 rather than 35 for the main cohort.

NICE's appraisal covers tirzepatide specifically. Semaglutide (Wegovy) carries a separate NICE recommendation under TA875, with its own conditions, including a maximum treatment duration of two years and access through a specialist weight management service. How NHS access to both medicines works in practice depends heavily on your local area.

Step 2: Match your profile to the active rollout cohort

NICE's approval did not open the door to everyone at once. NHS England is rolling access out in cohorts to manage demand and ensure wraparound lifestyle support is available alongside treatment. Here is where things stand.

From June 2025, the first cohort became eligible: adults with a BMI of 40 or above plus four or more of the five qualifying conditions. That is a high bar, and it deliberately targets the highest-risk group first.

From June 2026, Cohort 2 opened: adults with a BMI between 35 and 39.9 plus four or more of the five conditions. If you fit that profile, your GP may now be able to prescribe, subject to local availability and the wraparound care requirements.

The next planned phase (around March 2027) will cover adults with a BMI of 40 or above plus three qualifying conditions. Thresholds continue stepping down after that. Every NHS patient must take part in diet and activity support alongside the medicine, meeting the BMI and condition criteria does not guarantee access if that wraparound care is not yet in place locally. More on the NHS rollout timetable is available if you want the broader picture.

Step 3: Understand what happens if you do not yet qualify, or cannot wait

If you feel frustrated reading that and calculating whether your numbers fit, that is completely understandable. A lot of people are in the gap: they know these medicines could help, they have a weight-related condition, but their BMI or condition count does not quite reach the current NHS threshold, or their GP practice has not yet opted in to the new prescribing contract.

From April 2026, GP practices may prescribe tirzepatide under the updated GP contract, but this is optional rather than mandatory, and rollout is uneven across England. Scotland, Wales, and Northern Ireland operate under different criteria and access routes.

The practical alternative is a private prescription through a GPhC-registered pharmacy. Private prescribing follows the licensed eligibility criteria in the medicine's SmPC rather than the NHS cohort system: adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition, are within the licensed population. A prescriber still reviews every application individually. For context on what private treatment costs and what that price includes, the treatment overview has a clear breakdown, or you can look at the step-by-step guide to accessing these medicines privately.

It is worth being direct about one thing: obtaining a weight loss injection without a valid prescription is not a legal or safe route. These are prescription-only medicines, and the MHRA has warned publicly about counterfeit pens circulating online.

How to check whether you qualify, on the NHS or privately

The most reliable first step is to use the NHS BMI calculator to confirm your BMI, then review whether you have any of the five qualifying conditions listed above. If you meet current NHS criteria, a conversation with your GP is the right next step, ask specifically whether your practice is participating in the tirzepatide prescribing programme.

If you do not meet the NHS cohort thresholds but are within the licensed BMI range, a private consultation with a clinician-led service is worth considering. At nume, a GPhC-registered Independent Prescriber reads every consultation the same day, a real clinician, not an automated system. Our clinical team's approach is set out on the prescriber profile page if you want to understand who is reviewing your case. Find out more about whether you personally qualify for NHS treatment, or explore the full NHS eligibility criteria in detail before deciding your next move.

When you are ready, check your eligibility with our clinical team through a free consultation.